Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?
It is unclear whether differences exist in baseline serum galactomannan (sGM) in patients with hematologic malignancies and invasive pulmonary aspergillosis (IPA) caused by non-fumigatus Aspergillus species vs Aspergillus fumigatus. We found no differences in baseline sGM positivity rates, median sGM levels, and 42-day mortality in 72 such patients (Aspergillus fumigatus in 43 and non-fumigatus Aspergillus in 29).